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ORIGINAL ARTICLE VIROLOGYEpstein–Barr virus (EBV) DNA in whole blood as a superior prognostic
and monitoring factor than EBV-encoded small RNA in situ hybridization
in diffuse large B-cell lymphomaJ.-H. Liang1, T.-X. Lu1, T. Tian1, L. Wang1, L. Fan1, J. Xu1, R. Zhang1, Q.-X. Gong2, Z.-H. Zhang2, J.-Y. Li1 and W. Xu1
1) Department of Haematology and 2) Department of Pathology, the First Afﬁliated Hospital of Nanjing Medical University, Jiangsu Province Hospital,
Nanjing, ChinaAbstractEpstein–Barr virus (EBV) status was retrospectively analysed by the use of EBV-encoded small RNA (EBER) in situ hybridization (ISH) and EBV
DNA analysis in whole blood with diffuse large B-cell lymphoma, to assess the clinical signiﬁcance for diagnosis, prognostication, and
monitoring of tumour burden. Three hundred and twenty-nine patients were retrospectively enrolled, with 232 patients being available
for EBER ISH analysis, 189 patients for EBV DNA analysis, and 138 patients for both analyses. EBER was positive in 24 (10.3%) patients,
and EBV DNA was positive in 18 (9.5%) patients; the two analyses had 92.8% concordance. Patients with pretreatment EBER positivity
had worse overall survival (OS) than those without EBER positivity (p 0.03); the same pattern was observed for EBV DNA (p < 0.01). A
signiﬁcant p-value was also observed for OS when EBER and EBV DNA were combined (p < 0.01). On multivariate analysis, both EBV
DNA (hazard ratio 3.71, 95% CI 1.78–7.74, p < 0.01) and EBER (hazard ratio 2.03, 95% CI 1.03–4.00, p 0.04) remained independent
predictive factors for OS. Regarding the dynamic changes in copy number of elevated EBV DNA, the transformation from positive to
negative after cycle 3 with chemotherapy may have the most capacity to distinguish a superior from an inferior outcome. These ﬁndings
suggest that EBV DNA in whole blood has good concordance with EBER ISH, and that it may be a better prognostic and monitoring
biomarker than EBER.
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rights reserved.
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E-mail: xuwei10000@hotmail.comIntroductionEpstein–Barr virus (EBV), ﬁrst isolated by Epstein et al. [1] from
African Burkitt’s lymphoma cell lines, is a ubiquitous herpes-
virus with the special characteristic of being an apparent
oncogenic agent [2]. Many studies have shed light on the
involvement of EBV in the pathogenesis of several kinds ofMicrobiol Infect 2015; 21: 596–602
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.02.017lymphoma, including diffuse large B-cell lymphoma (DLBCL)
[2–5].
There is long-standing recognition of the correlation be-
tween DLBCL and EBV, with EBV-positive DLBCL of the
elderly having been included as a new provisional entity in
the 2008 WHO lymphoma classiﬁcation [6]. However, the
literature shows that epidemiological features correlate with
geographical differences, with there being a higher preva-
lence of EBV-positive DLBCL among East Asians (4.5–11.4%)
than in Western populations (1–3%) [7–10]. Furthermore,
EBV-positive DLBCL, including EBV-positive DLBCL of
the elderly, responds more poorly to treatment and
results in worse overall survival (OS) than EBV-negative
DLBCL [8].ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Liang et al. EBV DNA as a superior prognostic and monitoring factor 597EBV-encoded mRNA (EBER) in situ hybridization (ISH) is the
most common method used for detecting EBV status in DLBCL.
However, no uniform criteria for the percentage of EBV-
positive cells in EBV-positive DLBCL have been agreed upon
until now, resulting in difﬁculties in evaluating the true incidence
of disease prevalence [8,11,12]. It is worth noting that, other
than EBER, the quantiﬁcation of EBV DNA in peripheral blood
has been demonstrated to be useful for the diagnosis and
monitoring of EBV-associated lymphomas [13–16]. Further-
more, EBV DNA in peripheral blood detected by PCR could be
derived from two different samples, as follows: a liquid
component of plasma or serum, and a cell component of
mononuclear cells or whole blood. A prospective study re-
ported by Suzuki et al. [16] showed the prognostic and moni-
toring value of mononuclear cell EBV DNA to be similar to that
of plasma EBV DNA in extranodal natural killer cell/T-cell
lymphoma (NKTCL), nasal type, and it is generally accepted
that plasma EBV DNA is a better tumour marker than EBER
ISH in NKTCL and Hodgkin’s lymphoma (HL). However, not
only is there no literature on the clinicopathological features
and prognostic value of EBV DNA in DLBCL in comparison
with EBV DNA in whole blood and the conventional method of
EBER ISH, but there are also no reports on the signiﬁcance of
EBV DNA in EBV-negative patients according to the 2008
WHO classiﬁcation of lymphoma [6]; investigation of this was
the ﬁrst objective of our study.
Detection of EBV DNA by the use of whole blood specimens
has the advantage of convenience in terms of sample handing
and procurement, and monitoring of the dynamic changes in
EBV DNA loads, in comparison with EBER ISH. To address this
issue further, we also assessed the value of the dynamic changes
in EBV DNA in whole blood for DLBCL patients as a biomarker
for therapeutic response and prognostication after standard
treatments.Materials and methodsPatients
Three hundred and twenty-nine DLBCL patients who were
newly diagnosed between April 2005 and January 2013 were
retrospectively enrolled in our study. Baseline clinical charac-
teristics, including age, gender, Ann Arbor stage (I– IV), the
number of sites of extranodal involvement, lactate dehydroge-
nase, ECOG performance status, and B symptoms, were all
available. The International Prognostic Index was used for risk
stratiﬁcation. The Hans classiﬁcation of germinal centre B-cell
(GCB) or non-GCB type was used for the patients. The ﬁrst-
line treatments of all of the de novo DLBCL cases are shown
in Table S1.Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyEBV DNA analysis by real-time PCR
The peripheral whole blood sample was collected in an EDTA-
containing tube for each patient. DNA from whole blood was
extracted with the EBV PCR Fluorescence Quantitative Diag-
nostic Kit (Da An Gene Co., Sun Yat-sen University, China).
Quantiﬁcation of EBV-speciﬁc sequences was performed by
real-time quantitative PCR with ABI PRISM 7500 (Applied
Biosystems, Foster City, CA, USA). The copy number of EBV
DNA in each sample was calculated from a standard curve with
a cut-off value of 5 × 103 copies/mL.
EBER ISH
The presence of EBV was investigated with EBER ISH (EBER
PNA Probe, ISH-5022; ZSGB-BIO, Beijing, China). The study
was carried out on 3-μm-thick sections from parafﬁn-
embedded biopsy specimens. The parafﬁn-embedded tissue
sections were dewaxed in xylene, treated with proteinase K,
and hybridized with digoxigenin-labelled probe, with a cut-off
value of 50% EBV-positive cells for EBER positivity [8].
Statistical analysis
All statistical analyses were performed with SPSS for Windows
(version 17.0; IBM Corporation, Armonk, NY, USA). OS was
deﬁned as the time from diagnosis to death owing to any cause by
the end of follow-up. OS was evaluated with the Kaplan–Meier
method. A p-value of <0.05 was considered to be signiﬁcant.ResultsPatients’ clinical characteristics in relation to EBV
DNA and EBER
Three hundred and twenty-nine patients were retrospectively
enrolled in our study, with tumour tissue specimens of 232
(70.5%) patients being available for EBER ISH, and only 189
(57.4%) patients having pretreatment whole blood specimens
for EBV DNA analysis. EBER positivity was found in 24 (10.3%)
of the 232 patients, and EBV DNA positivity was found in 18
(9.5%) of the 189 patients. There were 138 (138/329, 41.9%)
patients for whom EBER status was available and whose EBV
DNA in whole blood was detected at presentation. Among all
the 138 patients, there were 128 (92.8%) patients whose EBER
ISH status and EBV DNA status were concordant; ten (7.8%)
patients were positive for both, and 118 (92.2%) patients were
negative for both. Discordant results were found in ten (7.2%)
patients; these are all shown in Table S2.
The baseline characteristics according to EBV status assessed
by EBER ISH and EBV DNA are described in Table 1. There was
a statistically signiﬁcant male dominance, based on both pre-
treatment EBV DNA and EBER (p 0.01 and p 0.03,and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 596–602
TABLE 1. Clinical characteristic according to Epstein–Barr virus (EBV)-encoded small RNA (EBER) and pretreatment EBV DNA
EBV DNA-positive, n EBV DNA-negative, n p EBER-positive, n EBER-negative, n p
Male sex 16/18 100/171 0.01 20/24 124/208 0.03
Age >50 years 15/18 96/171 0.12 19/24 138/208 0.25
ECOG PS 2–4 6/18 43/171 0.57 8/23 40/208 0.10
LDH >270 U/L 10/18 83/171 0.63 11/24 76/204 0.51
Stage II– IV 14/18 115/171 0.44 17/23 105/206 0.02
Extranodal sites >1 6/18 43/171 0.57 6/23 51/205 1.00
IPI score 3–5 6/18 62/171 1.00 10/23 57/204 0.15
B symptoms 10/18 73/171 0.33 11/23 72/204 0.06
Non-GCB 12/13 88/142 0.03 13/17 109/196 0.08
GCB, germinal centre B-cell; IPI, International Prognostic Index; LDH, lactate dehydrogenase.
598 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIrespectively). Twelve (92.3%) of 13 EBV DNA-positive patients
were classiﬁed as non-GCB type (p 0.03), and 13 (76.5%) of 17
of EBER-positive patients were classiﬁed as non-GCB type, with
a trend for statistical signiﬁcance (p 0.08).
Comparison of the prognostic values of pretreatment
EBV DNA and EBER
The follow-up results of the statuses of all 329 patients enrolled
in this study were obtained on the end date of September 2014,
with a median follow-up of 38 months (range, 19–114 months).
Ninety-nine patients (30.1%) died, and the 3-year estimated OS
was 68.0% ± 2.8% among all patients.
Not only did OS estimation differ between the EBER-positive
and EBER-negative groups, but also worse OS was observed in
the pretreatment EBV DNA-positive group than in the EBV
DNA-negative group (p 0.03 and p < 0.01, respectively); this is
shown in Fig. 1. In the 138 patients who were available for bothFIG. 1. Overall survival (OS) in relation to Epstein–Barr virus (EBV) status, ac
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectanalyses, a signiﬁcant p-value of <0.01 was also observed be-
tween the EBV-positive (deﬁned as EBV DNA-positive or
EBER-positive) group and the EBV-negative (deﬁned as EBV
DNA-negative and EBER-negative) group.
Three different multivariate models (model 1, model 2, and
model 3) were used to investigate the independent prognostic
value of EBV DNA, EBER, and EBV, respectively. The three
models included the same variables (treatment arm without
rituximab, sex, and International Prognostic Index score and its
components), except for EBV DNA for model 1, EBER for
model 2, and EBV for model 3. Multivariate analysis showed that
both EBV DNA (hazard ratio 3.71, 95% CI 1.78–7.74, p < 0.01)
and EBER (hazard ratio 2.03, 95% CI 1.03–4.00, p 0.04) were
independent prognostic factors for OS. Furthermore, EBV
positivity (hazard ratio 3.31, 95% CI 1.52–7.21, p < 0.01)
retained its signiﬁcance for worse OS in model 3. All of these
results are shown in Table 2.cording to EBV-encoded small RNA (EBER) and EBV DNA at diagnosis.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 596–602
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CMI Liang et al. EBV DNA as a superior prognostic and monitoring factor 599Evaluation of the prognostic value of the dynamic
quantitative changes in EBV DNA with therapy
For the 18 patients with elevated levels of pretreatment EBV
DNA, we evaluated EBV DNA as a tumour marker after each
cycle of treatment in the standard treatment of six cycles.
Detailed information on the 18 patients is shown in Table 3.
The median age of the 18 patients was 57 years (range, 31–75
years).
The dynamic continuous quantitative changes of all 18 pre-
treatment EBV DNA-positive patients, which were classiﬁed as
complete response (CR)/CR undeﬁned, partial response, and
no response (NR), are shown in Fig. 2. The median pretreat-
ment EBV DNA copy numbers of all 18 patients were
3.70 × 106/mL (range, 6.23 × 103/mL to 4.72 × 107/mL). Spe-
ciﬁcally, we can see that, in patients in the CR/CR-undeﬁned
group, the viral load had dropped to undetectable levels
immediately after the therapy of the ﬁrst cycle, and had never
risen to detectable levels. Similarly, in the partial response
group, the EBV DNA loads of the patients were almost at an
undetectable level after the third or fourth cycle. In contrast,
patients in the NR group all still had elevated levels of EBV
DNA after the third cycle, and some even had elevated levels
after the sixth cycle of standard treatment.
In order to determine the cycle in which the EBV DNA-
negative transformation (from detectable to undetectable
levels) could better predict survival outcomes for the patients
with pretreatment EBV DNA positivity, the log-rank survival
for cycles 1, 2 and 3 was analysed. The results revealed that
patients who were EBV DNA-negative had a markedly superior
OS to that of patients who were still EBV DNA-positive after
the third cycle (EBV DNA-negative/cycle 3) (p < 0.01; Fig. S1);
the p-value was 0.06 after the ﬁrst cycle and 0.70 after the
second cycle (data not shown). The estimated 2-year OS was
80.2% ± 12.8% for the EBV DNA-negative/cycle 3 group,
whereas no patients in the positive group were alive after 2
years. Further investigation also showed that EBV DNA-
negative/cycle 3 patients had a similar OS (p 0.66) to patients
whose pretreatment EBV DNA was negative.ri
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osEBV-positive DLBCL of the elderly is characterized by a high
age distribution, with an arbitrary cut-off of 50 years (median,
71 years; range, 50–91 years) in the current 2008 WHO
classiﬁcation [6]; the results from our study showed that the
median age of EBER-positive patients was 55 years (range,
22–75 years), and that of EBV DNA-positive patients was 57
years (range, 31–75 years). However, three EBV DNA-positive
patients were younger than 50 years (31, 45 and 47 years,Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 596–602
TABLE 3. The detailed information of 18 patients with pretreatment Epstein–Barr virus (EBV) DNA positivity
No. Age (years)/gender IPI score GCB/non-GCB EBER Treatment/cycles Response Outcome
1 31/M 3 Non-GCB + R-DA-EPOCH/6 CR Alive
2 73/F 5 Non-GCB + R-CHOP/6 CR Alive
3 60/M 1 Non-GCB + R-CHOP/4 CR Alive
4 58/M 2 NA + R-CHOP/7 CR Alive
5 53/M 3 Non-GCB NA R-CHOP/5 PR Alive
6 54/M 2 Non-GCB + R-CHOP/6 PR Alive
7 50/F 2 NA NA R-CHOP/4 PR Alive
8 64/M 5 Non-GCB NA R-CHOP/8 PR Dead
9 75/M 1 GCB + R-DA-EPOCH/6 NR Dead
10 55/M 1 Non-GCB + DA-EPOCH/6 NR Dead
11 55/M 0 Non-GCB + R-DA-EPOCH/6 NR Alive
12 55/M 1 NA NA CHOP/6 NR Dead
13 50/M 0 NA — R-CHOP/6 NR Dead
14 52/M 1 Non-GCB + R-CHOP/4 NR Dead
15 75/M 2 Non-GCB NA R-CHOP/5 NR Dead
16 72/M 5 Non-GCB NA R-CHOP/3 NR Dead
17 47/M 4 NA + R-CHOP/2 NR Dead
18 45/M 2 Non-GCB NA CHOP/3 NR Dead
CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete response; DA-EPOCH, dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine,
prednisone; EBER, Epstein–Barr virus-encoded small RNA; F, female; GCB, germinal centre B-cell; M, male; NA, not acquired; NR, no response; PR, partial response;
R-CHOP, rituximab plus CHOP; R-DA-EPOCH, rituximab plus DA-EPOCH.
600 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIrespectively), as were four EBER-positive patients (22, 39, 46
and 48 years, respectively); it has been previously reported in
the literature that younger patients can be also affected
[16–18]. Furthermore, no statistical signiﬁcance was observed
regarding age distribution (50 years vs. <50 years), as assessed
by either EBER or EBV DNA. Further investigations should be
focused on the clinical characteristics and survival outcomes ofFIG. 2. Serial analysis of quantitative Epstein–Barr virus (EBV) DNA in 18
undeﬁned (CRu), partial response (PR), and no response (NR).
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectEBV-positive DLBCL patients aged <50 years. The current
deﬁnition of EBV-positive DLBCL of the elderly [6] may face a
challenge if a substantial proportion of EBV-positive DLBCLs
are also observed in younger patients in other studies.
In contrast to another report from northern China showing
that the incidence of EBV positivity in patients with DLBCL aged
>50 years was only 3.8% (8/212), by using a cut-off of >50% EBERpatients categorized into three groups: complete response (CR)/CR
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 596–602
CMI Liang et al. EBV DNA as a superior prognostic and monitoring factor 601positivity, the incidence detected either by EBER (10.3%) or by
EBV DNA analysis (9.5%) from our centre was consistent with
the ﬁndings among East Asians (8.7–11.4%) reported in the past
[7,8,19]. Although 92.8% (128/138) concordance was observed
between pretreatment EBV DNA and EBER ISH, the relatively
high ratio (7.2%, 10/138) of the inconsistent status needs to be
explained. Considering one possible explanation for the
discrepancy between EBV DNA positivity and EBER negativity,
Kanakry et al. [20] suggested that, in patients with human im-
munodeﬁciency virus infection, chronic active EBV, organ
transplantation, and primary EBV infection, EBV DNA may
reﬂect the presence of virions rather than genomic viral DNA
released from the latently infected cells in HL. This may also apply
to patients with DLBCL. Analysis of the other circumstances
requires further investigations.
With respect to the prognostic value of EBER positivity, Park
et al. [21] reported that patients with EBV-positive DLBCL,
including EBV-positive DLBCL of the elderly, responded more
poorly to treatment,with aworse outcome regarding bothOS and
progression-free survival, than patients with EBV-negativeDLBCL.
In addition, signiﬁcantly worse survival was observed in EBV-
positive DLBCL patients if CD30 expression was also observed
[22]. However, a negative impact of EBV infection on DLBCL
survival was not observed in North American patients [20].
In this study, pretreatment EBV DNA in whole blood and
EBER showed 92.8% concordance, which was similar to the
96% concordance between plasma EBV DNA and EBER in HL
reported by Kanakry [20]. Signiﬁcantly inferior OS was
observed in patients with positive EBV status assessed by EBV
DNA than in patients with positive EBV status detected by
EBER (p < 0.01 vs. p 0.03, respectively). Although both EBV
DNA and EBER were independent predictors of worse OS, we
still found that the hazard ratio for EBER was inferior to that for
EBV DNA, indicating that EBV DNA at diagnosis may be a
better prognostic biomarker for OS than the EBER ISH
conventionally used in the past. All of these results indicate that
EBV DNA is a good indicator for OS, which is similar to the
suggestion of Suzuki regarding extranodal NKTCL, nasal type
[16]. It is speculated that the positive EBV status detected either
by EBV DNA analysis or by EBER has prognostic signiﬁcance.
Just as we had expected, statistical signiﬁcance was also
observed between the EBV-positive and EBV-negative groups,
demonstrating that the combination of EBV DNA analysis and
EBER might be ﬁnally adapted in the clinic in the future.
After analysing each cycle, we found that the EBV DNA
status after cycle 3 might be the cut-off for the prognosis of OS
rather than the status after the other cycles. We also found that
patients who were EBV DNA-negative after cycle 3 had similar
results to those of patients whose pretreatment EBV DNA wasClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologynegative. Therefore, EBV DNA could be used as a monitoring
biomarker.
It needs to be emphasized that continuous monitoring is
necessary for patients who are EBV DNA-negative after cycle 3,
because patients may have worsened survival if the elevated
level is detected at any time after cycle 3, as we can observe
from patient 9 in the NR group. These patients may be treated
in the same way as poor-risk patients, and the superiority of
high-dose chemotherapy with stem cell support over conven-
tional methods should be investigated.
To summarize, the retrospective nature of this study, with
incomplete data, such as not all patients being available for both
analyses (EBER and EBV DNA), is the major limitation. From
this study, we can conclude that baseline EBV DNA-positive
DLBCL patients have worse OS. Additionally, given the fact
that the presence of EBV DNA negativity after cycle 3 of the
standard therapy appeared to be vital for these patients in the
current study, further larger prospective studies are worth
performing, to validate the value of EBV DNA as either a
prognostic factor at diagnosis or a monitoring biomarker with
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